Market open

Contineum Therapeutics/CTNM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Contineum Therapeutics

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Ticker

CTNM
Trading on

Industry

Pharmaceuticals

Employees

31

CTNM Metrics

BasicAdvanced
$445M
Market cap
-
P/E ratio
-$2.61
EPS
-
Beta
-
Dividend rate
$445M
$22.00
$13.27
81K
58.925
58.479
0.052
0.274
1.86
1.86
-3.963

What the Analysts think about CTNM

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Contineum Therapeutics stock.

CTNM Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CTNM Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy CTNM

$

Sign up or log in to buy
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Contineum Therapeutics stock?

Contineum Therapeutics (CTNM) has a market cap of $445M as of October 08, 2024.

What is the P/E ratio for Contineum Therapeutics stock?

The price to earnings (P/E) ratio for Contineum Therapeutics (CTNM) stock is 0 as of October 08, 2024.

Does Contineum Therapeutics stock pay dividends?

No, Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders as of October 08, 2024.

When is the next Contineum Therapeutics dividend payment date?

Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders.

What is the beta indicator for Contineum Therapeutics?

Contineum Therapeutics (CTNM) does not currently have a Beta indicator.